Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT Single photon emission computed tomography

Movement Disorders

Volumn 26, Issue 3, 2011, Pages 416-423

  Eggers, Carsten ^a   Kahraman, Deniz ^a   Fink, Gereon R ^a,b   Schmidt, Matthias ^a   Timmermann, Lars ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

Iodine 123 fluoropropyl carbomethoxy 3 single photon emission computed tomography; Parkinson subtype; Parkinson's disease; Visual analysis

Indexed keywords

IODINE 123; LEVODOPA; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; AKINESIA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RIGIDITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREMOR;

AGED; BRAIN MAPPING; CORPUS STRIATUM; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; MUSCLE RIGIDITY; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREMOR; TROPANES;

EID: 79953267610     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23468     Document Type: Article

References (25)

1. Young AB, Penney JB. Biochemical and functional organization of the basal ganglia. In: Parkinsons's disease and movement disorders ( 4th ed.). Jankovic J and Tolosa E (eds.). Philadelphia, PA: Lippincott Williams and Wilkins. 2002; pp 1-10.
2. Timmermann L, Gross J, Dirks M, et al. The cerebral oscillatory network of parkinsonian resting tremor. Brain 2003; 126: 199-212.
3. Rajput AH, Voll A, Rajput ML, et al. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 2009; 73: 206-212.
4. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001; 58: 1611-1615.
5. Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002; 59: 1724-1728.
6. Jellinger KA. Post mortem studies in Parkinson's disease-is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999; 56: 1-29.
7. Spiegel J, Hellwig D, Samnick S, et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. J Neural Transm 2007; 114: 331-335.
8. 123I]-FP-CIT study group. Mov Disord 2000; 15: 503-510.
9. Breit S, Reimold M, Reischl G, et al. [(11)C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. J Neural Transm 2006; 113: 187-193.
10. Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 1992; 42: 1554-1560.
11. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991; 9: 43-49.
12. Niznik HB, Fogel EF, Fassos FF, Seeman P. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991; 56: 192-198.
13. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
14. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
15. Fahn S. Elton RL, motUDC, editors.The Unified Parkinson's disease Rating Scale. Florham Park (NJ): McMillan Healthcare Information, 1987; Vol. 2.
16. Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343-348.
17. 123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13: 295-309.
18. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005; 46: 1109-1118.
19. Tatsch K, Asenbaum S, Bartenstein P, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging 2002; 29: BP30-BP35.
20. Morton RJ, Guy MJ, Clauss R, et al. Comparison of different methods of DatSCAN quantification. Nucl Med Commun 2005; 26: 1139-1146.
21. 123I-N-omega-fluoropropyl-2-beta-carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes. Nucl Med Commun 2009; 30: 194-201.
22. Efron B, Tibshirani RJ. An introduction to the bootstrap. London: Chapman & Hall; 1993.
23. Rajput AH, Sitte HH, Rajput A, et al. Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology 2008; 70: 1403-1410.
24. 123I-FP-CIT images. J Nucl Med 2007; 48: 1459-1467.
25. 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2008; 35: 1367-1376.